Luigiana Luciano

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

Fabio Efficace, Michele Baccarani, Massimo Breccia et al. · Leukemia · 2013 · 135 citations

Hematological Malignancy, Quality Of Life, Important Factor +11

Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.

Giovanni Barosi, Achille Ambrosetti, Antonietta Centra et al. · PubMed · 1998 · 121 citations

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Monica Bocchia, Anna Sicuranza, Elisabetta Abruzzese et al. · Frontiers in Oncology · 2018 · 105 citations · Full text

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

Roberta La Starza, Giorgina Specchia, Antonio Cuneo et al. · PubMed · 2005 · 66 citations

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese et al. · Hematological Oncology · 2019 · 66 citations · Full text